Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical
activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous
MTAP deletion.
Phase:
Phase 1
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc. Institut de Recherches Internationales Servier